271 related articles for article (PubMed ID: 24831915)
1. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
[TBL] [Abstract][Full Text] [Related]
2. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
Levin P; Wei W; Miao R; Ye F; Xie L; Baser O; Gill J
Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
[TBL] [Abstract][Full Text] [Related]
3. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
Xie L; Wei W; Pan C; Du J; Baser O
Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
[TBL] [Abstract][Full Text] [Related]
4. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
5. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
6. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
7. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
[TBL] [Abstract][Full Text] [Related]
8. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
[TBL] [Abstract][Full Text] [Related]
10. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
11. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
12. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
[TBL] [Abstract][Full Text] [Related]
13. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
14. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
[TBL] [Abstract][Full Text] [Related]
15. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
Xie L; Wei W; Pan C; Baser O
J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
[TBL] [Abstract][Full Text] [Related]
16. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
17. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
19. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Bailey TS; Wu J; Zhou FL; Gupta RA; Menon AA; Berhanu P; Westerbacka J; Van Vleet J; Blonde L
Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
[TBL] [Abstract][Full Text] [Related]
20. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
